[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Kyrgyzstan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":280},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,83,111,146,171,200,223,247],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100647852","integrating-evidence-based-approaches-to-prevent-child-maltreatment-in-kyrgyzstan-100647852",false,"NCT07712822","Integrating Evidence-based Approaches to Prevent Child Maltreatment in Kyrgyzstan","Inclusion Criteria:\n\n* Two adult caregivers (≥18 years old) who identify as co-parents or primary caregivers of a target child\n* Target child aged 6-9 years enrolled in one of the participating schools in Bishkek, Kyrgyzstan\n* Both caregivers identify each other as family members responsible for the care of the child (e.g., parents, grandparents, or other adult caregivers)\n* Both caregivers report feeling safe participating together in a family-based program\n* Both caregivers are fluent in either Russian or Kyrgyz\n* Both caregivers are able and willing to provide informed consent\n* Child is able to provide assent and participate in age-appropriate assessments.\n* Family is willing to participate in study procedures, including random assignment and completion of assessments at baseline, post-intervention (16 weeks), and end-of-school-year follow-up.\n\nExclusion Criteria:\n\n* Report of severe physical or sexual intimate partner violence between caregivers within the past 12 months, as assessed during screening\n* Either caregiver is unable to provide informed consent\n* Either caregiver has a cognitive impairment or a severe mental health condition that would preclude participation in group sessions\n* Family plans to relocate outside the study area during the intervention period\n* Child has a severe developmental or medical condition that would prevent participation in assessments\n* Inability to communicate in Russian or Kyrgyz.",true,"ALL","6 Years","74 Years",{"count":20,"type":21},396,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if a family-based prevention program works to prevent child maltreatment risk and other adverse childhood experiences (ACEs) among families in Kyrgyzstan. It will also learn about the safety, feasibility, and acceptability of the program. The main questions it aims to answer are: (1) Does the integrated family and economic empowerment program improve children's self-regulation, behavioral adjustment, and school adaptation? (2) Is the program feasible and acceptable for families and schools in Kyrgyzstan?\n\nResearchers will compare the integrated prevention program to bolstered standard school services to see if the program improves child and family outcomes. Participants will: (a) Be randomly assigned to either the prevention program or bolstered standard school services; (b) Attend weekly group sessions for 16 weeks (if assigned to the prevention program); (c) Complete surveys at baseline, immediately after the 16-week program, and at the end of the school year; and (d) Provide information about child behavior, (co)parenting, family relationships, and financial well-being.\n\nResults from this pilot study will inform a future larger trial.",[27,28],"Parent-Child Relationships","Child Maltreatment",[30,31,32],"child maltreatment","prevention","Kyrgyzstan","RECRUITING","2026-07-14",{"date":36,"type":37},"2026-07-20","ACTUAL",{"date":39,"type":21},"2026-09-01",{"date":41,"type":21},"2027-12-31",{"name":43,"class":44},"The University of Texas at Arlington","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100613083","crp-and-patient-information-leaflets-to-optimise-antibiotic-treatments-for-adults-with-respiratory-tract-infections-in-primary-care-in-kyrgyzstan-100613083","NCT07261969","CRP and Patient Information Leaflets to Optimise Antibiotic Treatments for Adults With Respiratory Tract Infections in Primary Care in Kyrgyzstan","2CARE INSTALL","Inclusion Criteria:\n\n* Adults aged 18 to 70 years with ARTI according to the attending HCW;\n* Having at least one of the following respiratory symptoms lasting for less than 2 weeks (with or without a fever):\n\n  * cough;\n  * shortness of breath;\n  * sore throat;\n  * stuffy nose;\n  * wheezing.\n* Able and willing to comply with all study requirements.\n* Able and willing to give informed consent.\n\nExclusion Criteria:\n\n* Severely ill and in need of urgent referral where measurement of POCT CRP is not relevant or would delay the process;\n* Terminally ill patients;\n* Patients with known immunosuppression or severe chronic disease (HIV, liver failure, kidney failure, history of neoplastic disease, long term systemic steroid use or similar conditions as assessed by the health worker or research team);\n* Patients who are not able to participate in follow-up procedures (lack of telephone etc.);\n* Have taken antibiotics within 24 hours before the index consultation;\n* Pregnant women;\n* Unable or unwilling to provide informed consent.","18 Years","70 Years",{"count":56,"type":21},1050,[24],"This study aims to determine how CRP levels and Patient Information Leaflets (PILs) affect antibiotic prescribing in adults with acute respiratory symptoms in Kyrgyz primary care. It will evaluate the effectiveness of PILs in reducing antibiotic use and ensuring safety and assess the effectiveness and safety of three CRP thresholds (20, 40, 60 mg\u002FL) for adults with acute respiratory tract infections. Conducted as a multicentre, open label, individually randomized controlled clinical trial with 21 days of blinded follow-up, the study will compare PIL to no PIL in a 1:1 ratio and assess antibiotic use and safety across the three CRP cut-offs in a 1:1:1 ratio, resulting in six groups. The trial will take place in 14 district primary healthcare centres in rural Kyrgyzstan and one urban primary healthcare centre in Bishkek.",[60,61,62,63,64],"Respiratory Tract Infection Bacterial","Respiratory Tract Infection Viral","AMR","CRP","Inflammation",[66,67,68,69,70,71,72],"CRP POCT","Primary care","ARVI","ARTI","Adults","PIL","RCT","2025-11-29",{"date":75,"type":37},"2025-12-03",{"date":77,"type":37},"2024-12-18",{"date":79,"type":21},"2027-04-30",{"name":81,"class":44},"Rigshospitalet, Denmark",2,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100483779","expanding-medication-assisted-therapies-in-central-asia-100483779","NCT05579470","Expanding Medication-Assisted Therapies in Central Asia","ExMAT CA","Inclusion Criteria:\n\ni. Aim 1: The inclusion criteria for Aim 1 Consists of:\n\n1. Quantitative surveys for PWID\n\n   1. 18 years or older\n   2. Meeting DSM-V criteria for opioid dependence\n   3. Be either treatment naïve and seeking OAT or be on OAT for \\\u003C 90 days\n2. Organizational Assessments for OAT Delivery Staff\n\n   1. 18 years or older\n   2. Currently working as an OAT delivery professional at an OAT delivery site\n3. Focus Groups (PWID on OAT)\n\n   1. 18 years or older\n   2. Meeting DSM-V criteria for opioid dependence\n   3. Be either treatment naïve and seeking OAT or be on OAT for \\\u003C 90 days\n4. Focus Groups (PWID not on OAT)\n\n   1. 18 years or older\n   2. Meeting Diagnostic and Statistical Manual of Mental Disorders(DSM)-V criteria for opioid dependence\n   3. Be OAT naïve (defined as never having been on OAT or having not received treatment for \\> 1 year)\n5. Focus Groups (OAT delivery staff)\n\n   1. 18 years or older\n   2. Currently working as an OAT delivery professional at an OAT delivery site\n\nii. Aim 2: The inclusion criteria for Aim 2 consists of:\n\n1. 18 years or older\n2. Currently assigned as a Chief Narcologist for an Oblast\n\niii. Aim 3: The inclusion criteria for Aim 3 consists of:\n\n1. 18 years or older\n2. Authorized as a professional to work at an OAT delivery site\n\nExclusion Criteria:\n\n* Not willing to provide consent",{"count":91,"type":21},900,[24],"Central Asia (CA) represents the most rapidly growing HIV epidemic region worldwide, concentrated in people who inject drugs (PWID) and their sexual partners, and scaling up opioid agonist therapies (OAT) in this region is the most cost-effective strategy to prevent new HIV infections, and more effective when combined with antiretroviral therapy (ART). The investigators propose to use the Network for the Improvement of Addiction Treatment (NIATx) implementation strategy to scale-up OAT in three diverse Central Asian countries (Kazakhstan, Kyrgyzstan, Tajikistan) and guided by the Exploration-Planning-Implementation-Sustainment (EPIS) framework. Understanding the trajectories of implementation and scale-up in this context may emerge through creating communities of practice, especially when cohesion and competence evolves, and may guide other healthcare delivery challenges in the region (e.g., HIV, TB); as well as build important regional expertise and understanding implementation trajectories should help support OAT program sustainability.",[95],"Opioid Use Disorder",[97,98,99,100],"HIV","OUD","OAT","Central Asia","2025-09-16",{"date":103,"type":37},"2025-09-22",{"date":105,"type":37},"2023-08-07",{"date":107,"type":21},"2026-12-31",{"name":109,"class":44},"Yale University",4,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":15,"sex":16,"minAge":53,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":123,"conditions":124,"keywords":130,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":45},"100602050","phase-4-highcycle-study-acetazolamide-high-altitude-and-plasma-volume-100602050","NCT07118462","HighCycle Study: Acetazolamide, High Altitude and Plasma Volume","HighCycle Study: Effect of Acetazolamide on Plasma Volume During Acute Exposure to High Altitude in Women and Men","Inclusion Criteria:\n\n* Healthy, non-smoking men and women, age 18-44 years, without any disease and need of regular medication (including oral contraceptives).\n* BMI \\>18 kg\u002Fm2 and \\\u003C30 kg\u002Fm2.\n* Born, raised and currently living at altitudes \\\u003C1000 m.\n* Written informed consent.\n* Premenopausal women with an eumenorrheic cycle.\n\nExclusion Criteria:\n\n* Other types of contraceptvies (contraceptives (hormonal intrauterine device, vaginal ring, subcutaneous injections or implants, among others).\n* Pregnancy or nursing\n* Anaemic (haemoglobin concentration \\\u003C10g\u002Fdl).\n* Any altitude trip \\\u003C4 weks before the study.\n* Allergy to acetazolamide and other sulfonamides.","44 Years",{"count":120,"type":21},270,[122],"PHASE4","Each year, millions of people living at low altitude (\\\u003C 1,000 m) travel to high altitude (≥ 2,500 m) for work, tourism, or sports activities. These individuals are exposed to hypobaric hypoxia, which can trigger acute mountain sickness (AMS)-the most common form of altitude-related illness. Therefore, understanding the physiological responses to hypoxia that allow acclimatization, as well as the pathophysiology of acute mountain sickness, is of primary importance.\n\nThe hematological response to high-altitude exposure initially includes a reduction in plasma volume (PV), leading to an early increase in hemoglobin concentration within the first 24 hours. In contrast, an increase in hemoglobin mass requires several weeks at high altitude. Recent well-controlled physiological studies conducted in hypobaric chambers have demonstrated that this hypoxia-induced PV contraction results from fluid redistribution from the intravascular to the extravascular compartment, rather than from water loss due to increased diuresis.\n\nProphylaxis of AMS is primarily based on the administration of 250 mg\u002Fday of acetazolamide (ACZ), a carbonic anhydrase inhibitor with a mild diuretic effect. Acetazolamide induces metabolic acidosis, which stimulates ventilation and thereby improves oxygenation. The effect of prophylactic ACZ use during high-altitude exposure on PV in lowlanders remains unknown: it is unclear whether ACZ leads to a greater reduction in PV due to its diuretic effect, or to a smaller hypoxia-induced PV contraction as a result of improved oxygenation induced by increased ventilation.",[125,126,127,128,129],"High Altitude Effects","High Altitude Hypoxia","Acute Mountain Sickness (AMS)","Plasma Volume","Women",[131,132,133,134,135,136],"acetazolamide","plasma volume","acute mountain sickness","high altitude","hypoxia","women","2025-08-11",{"date":139,"type":37},"2025-08-12",{"date":141,"type":37},"2024-07-15",{"date":143,"type":21},"2025-12-31",{"name":145,"class":44},"Centre d'Expertise sur l'Altitude EXALT",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":169,"locationsCount":82},"100597828","effect-of-rehabilitation-at-moderate-altitude-on-airway-resistance-measured-with-forced-oscillation-technique-in-copd-patients-100597828","NCT07063563","Effect of Rehabilitation at Moderate Altitude on Airway Resistance Measured With Forced Oscillation Technique in COPD-patients","Effect of Rehabilitation at Moderate Altitude on Airway Resistance Measured With Forced Oscillation Technique in Patients With COPD","Inclusion Criteria:\n\n* Aged ≥18 years\n* Stable clinical condition for \\>3 weeks (e.g., no exacerbations)\n* Resting SpO₂ ≥88% and exercise-induced hypoxemia defined as a drop in SpO₂ of ≥4% and\u002For a level below 90% during the 6MWT\n* Informed consent documented by signature\n\nExclusion Criteria:\n\n* Severe daytime resting hypoxemia (SpO₂ \\\u003C88%)\n* Long-term oxygen therapy\n* Unstable clinical condition requiring adjustment of pharmacological or other treatment modalities, need for intensive care, or presence of relevant severe comorbidities\n* Inability to comply with study procedures (e.g., due to language barriers, psychological disorders, neurological or orthopedic impairments, walking disability, or inability to ride a bicycle)\n* Women who are pregnant or breastfeeding\n* Enrolment in another clinical trial involving active treatment",{"count":154,"type":21},52,[24],"Airway resistance will be measured using the forced oscillation technique (FOT). The parameters Rrs, Xrs, and ∆Xrs will be compared before and after a pulmonary rehabilitation cycle at moderate altitude. Additionally, the differences between low and moderate altitude will also be examined.",[158],"COPD",[160,161,162],"Oxygen","Exercise","Rehabilitation","2025-07-16",{"date":165,"type":37},"2025-07-20",{"date":167,"type":21},"2025-07-23",{"date":143,"type":21},{"name":170,"class":44},"Eastern Switzerland University of Applied Sciences",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":5},"100590718","vacuum-assisted-laser-ablation-vala-for-treatment-of-large-saphenous-veins-100590718","NCT06971068","Vacuum-assisted Laser Ablation (VALA) for Treatment of Large Saphenous Veins","Endovenous Vacuum-assisted Laser Ablation (VALA) in the Treatment of Large Saphenous Veins (> 15 mm)","Inclusion Criteria:\n\n* Age over 18 years\n* Varicose veins of the lower extremities with clinical class C2-C6 with a diameter of the GSV or SSV ≥ 15 mm in a standing position\n* Informed consent\n\nExclusion Criteria:\n\n* pregnancy or lactation\n* malignant neoplasms\n* inability or unwillingness of any patient to wear compression stockings\n* hypersensitivity to lidocaine\n* concomitant diseases: diabetes mellitus, bronchial asthma, severe liver and kidney diseases, acute thrombosis and thrombophlebitis, skin and\u002For soft tissue infection, infectious diseases, obliterating peripheral arteriosclerosis, diabetic angiopathy, heart defects requiring surgical intervention, fever, toxic hyperthyroidism, obesity, tuberculosis, sepsis, blood cell composition disorder, all diseases requiring bed rest, heart disease with decompensation, known hereditary thrombophilia\n* period after treatment for alcohol addiction\n* sedentary lifestyle\n* history of acute deep vein thrombosis\n* history of superficial thrombophlebitis\n* history of drug or other addiction\n* use of oral contraceptives or other hormonal drugs","90 Years",{"count":180,"type":21},184,[24],"Endovenous thermal ablation (EVTA), including radiofrequency ablation (RFA) and endovenous laser ablation (EVLA), is considered the main method for the treatment of symptomatic truncal vein reflux. However, there are controversial data concerning their efficacy and safety in ablating large saphenous veins because of high risk of heat-induced thrombosis (EHIT), incomplete ablation and recanalization.1-5 The use of vacuum evacuation of the remaining intraluminal blood during endovenous laser ablation allows to decrease the risk of intraoperative (carbonization and destruction of the fiber lens) and postoperative complications (EHIT, hyperpigmentation, \"string\" feeling) and leads to reduction of recovery because of short period of vein resorption. The aim of the study is to evaluate the safety and effectiveness of endovenous thermal ablation with or without vacuum evacuation for the treatment of incompetent large saphenous veins (\\>15 mm).",[184],"Varicose Veins",[186,187,188,189],"Vacuum-assisted Laser Ablation","large saphenous veins","varicose veins","EVLA","2025-05-10",{"date":192,"type":37},"2025-05-14",{"date":194,"type":37},"2025-03-15",{"date":196,"type":21},"2026-02-15",{"name":198,"class":199},"Center Of Phlebology","NETWORK",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":222},"100590024","pride-iii-prison-interventions-and-hiv-prevention-collaboration-100590024","NCT06962033","PRIDE III Prison Interventions and HIV Prevention Collaboration","PRIDE III","Inclusion Criteria:\n\nAim 1:\n\n1. Quantitative surveys for prison OAT providers\n\n   * Being 18 years or older\n   * Being currently assigned and working as a probation OAT provider for a probation site\n2. ECHO procedures\n\nAim 2:\n\n1. Quantitative surveys for people in probation\n\n   * Being 18 years or older\n   * Screen yes to opioid injection on the online screener questionnaire\n   * Currently in probation\n2. Quantitative surveys for probation and prison officers\n\n   * Being 18 years or older\n   * Being currently assigned and working as a probation or prison officer at a probation site\n3. Focus Groups (People in probation)\n\n   * Being 18 years or older\n   * Screen yes to opioid injection criteria on the online screener\n   * Currently in probation\n4. Focus Groups (Probation and prison officers)\n\n   * Being 18 years or older\n   * Being currently assigned and working as a probation or prison officer at a probation\n   * Has more than 3 months of field experience\n   * Works at a probation site within 25 kilometers of an OAT site\n\nExclusion Criteria:\n\n\\-",{"count":208,"type":21},300,[24],"The primary objective of this research project is to identify barriers to scale-up of Opioid Agonist Therapy (OAT) in the justice systems (prisons and probation) in Tajikistan, Kyrgyzstan, Moldova, and Georgia, and establish a NIATx learning collaborative to scale-up OAT, and analyze scale-up utilizing latent class growth analyses in people who inject drugs (PWID).",[212,213],"Hiv","Opioid Use","2025-05-08",{"date":216,"type":37},"2025-05-11",{"date":218,"type":37},"2024-11-05",{"date":220,"type":21},"2028-12",{"name":109,"class":44},5,{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":229,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":45},"100581273","early-phase-1-study-of-the-effectiveness-and-safety-of-embolization-of-the-middle-meningeal-artery-using-non-adhesive-materials-squid-12-and-squid-18-in-the-treatment-of-patients-with-chronic-resistant-migraine-100581273","NCT06848166","Study of the Effectiveness and Safety of Embolization of the Middle Meningeal Artery Using Non-adhesive Materials SQUID 12 and SQUID 18 in the Treatment of Patients With Chronic Resistant Migraine","Inclusion Criteria:\n\n1. The patient has read, understood, signed, and dated the Patient Information Sheet with the informed consent form.\n2. The patient is aged between 35 and 59 years inclusive at the time of signing the Patient Information Sheet with the informed consent form.\n3. The diagnosis of \"chronic migraine\" according to the clinical guidelines on migraine by the Ministry of Health of the Russian Federation (2021) \u002F ICD-10 (2018), established at least 12 months before screening.\n4. Resistant nature of the migraine, determined by the doctor using the criteria of the European Headache Federation (EHF, 2020), established at least 6 months before screening.\n5. At least 14 days of headache during the screening period (28 days), of which 8 days of headache meet the definition of migraine (assessed based on the results of filling out the Headache Diary for 28 days during the screening period).\n6. Migraine, resistant to both pharmacological and non-pharmacological prevention and treatment methods, in the patient's history.\n7. Maximum level of headache during migraine days above 5 points (inclusive) on a 10-point numerical rating scale during the screening period.\n8. No positive effect on migraine symptoms (frequency and intensity of headache attacks) from previous botulinum toxin therapy (administration of OnabotulinumtoxinA, Relatox® (botulinum toxin type A - hemagglutinin complex 155 - 195 IU, administered every 12 weeks according to the PREEMPT protocol).\n9. Consent to use adequate contraceptive methods\\* and not serve as an egg\u002Fsperm donor from the time of signing the Patient Information Sheet with the informed consent form for participation in the study until the end of the study (for women with reproductive potential and men).\n\nExclusion Criteria:\n\n1. The patient has contraindications to undergoing embolization of the middle meningeal artery based on the medical history, results of examinations, and laboratory tests conducted during screening.\n2. Allergic reactions to contrast agents used during procedures before\u002Fduring the embolization procedure and associated procedures.\n3. The patient has a history of cerebral vascular malformations, arteriovenous malformations, brain aneurysms, brain tumors, hydrocephalus, arachnoiditis, cerebrospinal fluid circulation disorders, craniovertebral junction anomalies, platybasia, skull base deformities, severe traumatic brain injuries, stenosis, and occlusion of pre-cerebral arteries.\n4. The patient has a history of skull base fractures and consequences of skull base fractures, history of neurosurgical operations.\n5. A history of mental illness (including depression, confirmed by a psychiatrist during screening through the HADS questionnaire and Hamilton scale assessment), which, in the opinion of the psychiatrist, may affect the patient's ability to assess their condition, interfere with participation in the study, or impact the patient's safety during the study.\n6. A history of hyperthyroidism or diabetes. The presence of other endocrine disorders in the patient's history that, in the doctor's opinion, could interfere with participation in the study or affect the evaluation of efficacy and\u002For safety.\n7. History or data of drug addiction, alcoholism, or abuse of medications.\n8. Medication-induced headache at the time of screening and within 3 months (12 weeks) prior to screening.\n9. Other types of chronic headache in the patient's history within less than 12 months before screening, such as trigeminal autonomic cephalalgias (including cluster headaches, prolonged hemicrania), new daily persistent headaches, painful cranial neuropathies, retinal migraine, aura without headache, hemiplegic migraine, brainstem aura migraine, idiopathic intracranial hypertension without optic nerve edema, spontaneous intracranial hypertension, secondary headaches.\n10. The patient is unable to distinguish a migraine headache from other types of headache.\n11. The patient has migraine complications, such as status migrainosus, persistent aura without infarction, migraine infarction, migraine aura (as a trigger for epileptic seizures).\n12. Body mass index (BMI) below 18.5 or above 39.9 kg\u002Fm².\n13. The onset of migraine was diagnosed at an age older than 50 years.\n14. The presence of metabolic syndrome or cachexia.\n15. Severe cardiovascular diseases currently or in the past, including: chronic heart failure class III or IV (according to the New York Heart Association classification), clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation), significant heart valve diseases, uncontrolled hypertension with systolic blood pressure \\> 180 mm Hg and diastolic blood pressure \\> 110 mm Hg, pulmonary embolism, or deep vein thrombosis.\n16. Varicose veins of the lower limbs, history of lower limb vein thrombosis.\n17. Ischemic heart disease, atherosclerosis of coronary vessels.\n18. Stenotic atherosclerosis of brachiocephalic arteries in the patient's history.\n19. Acute cerebrovascular accident or its consequences in the patient's history.\n20. The patient is pregnant or plans to become pregnant within the next 3 months.\n21. Atrial fibrillation, patent foramen ovale, anomalies of the interatrial septum, history of heart and coronary vessel surgeries.\n22. Signs of blood clotting disorders in the patient's history and screening, history of antiphospholipid syndrome.\n23. Use of anticoagulant drugs less than 5 days before the procedure.\n24. Uncontrolled bronchial asthma, severe chronic obstructive pulmonary disease in the patient's history.\n25. Renal insufficiency at screening based on the calculation of glomerular filtration rate (GFR) ≤ 60 mL\u002Fmin, based on serum creatinine levels at screening, or a history of renal insufficiency.\n26. History of liver insufficiency, elevated ALT and AST levels at screening.\n27. History of generalized pain syndrome, fibromyalgia.\n28. For women: use of combined oral contraceptives with a history of thrombosis of any localization.\n29. History of epilepsy, epileptic syndrome, seizure disorders, neurological conditions other than the primary condition (migraine).\n30. Presence of antibodies to HIV, hepatitis C virus, hepatitis B surface antigen (HbsAg), antibodies to T. Pallidum, or a history of HIV infection, hepatitis B, hepatitis C, or syphilis, either in the medical history or based on the results of serological blood tests at screening.\n31. Malignant neoplasms within 5 years before screening, or current or suspected oncological disease.\n32. Other serious, unstable, decompensated, or clinically significant medical or psychological conditions that, in the opinion of the doctor, may interfere with the patient's participation in the study or affect the evaluation of efficacy and\u002For safety.\n33. Participation in other interventional clinical trials, including the study completion visit, within 30 days prior to the screening, or planning to participate in such studies during the current study. Participation in non-interventional registry or epidemiological studies is allowed.\n34. The patient is unable to read or write, unwilling or unable to comply with the study protocol procedures; any other conditions that, in the opinion of the doctor, may prevent participation in the study, adherence to procedures, or contradict the patient's interests, as well as affect the study results.\n35. Employees of the medical institution conducting the study or the sponsor company, their family members, or subjects in dependent relationships.","35 Years","59 Years",{"count":232,"type":21},30,[234],"EARLY_PHASE1","To evaluate the effectiveness and safety of middle meningeal artery (MMA) embolization using non-adhesive materials SQUID 12 and SQUID 18 as a treatment method for patients with chronic resistant migraine.",[237],"Chronic Migraine Headache","2025-02-21",{"date":240,"type":37},"2025-02-26",{"date":242,"type":37},"2024-10-25",{"date":244,"type":21},"2027-05",{"name":246,"class":44},"Vedanta University Clinic",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":16,"minAge":229,"maxAge":54,"enrollmentInfo":254,"targetDuration":4,"studyType":256,"phases":4,"briefSummary":257,"conditions":258,"keywords":268,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":279},"100303086","prospective-urban-rural-epidemiology-study-100303086","NCT03225586","Prospective Urban Rural Epidemiology Study","PURE","Inclusion Criteria:\n\n* consenting adults between 35-70 years of age\n\nExclusion Criteria:\n\n* none",{"count":255,"type":21},200000,"OBSERVATIONAL","To examine the impact of health determinants at the individual (e.g. health related behaviors) and societal level (e.g. environmental factors, health related policy, quality of health systems) on health outcomes (e.g. death, non-communicable disease development) across a range of socioeconomic and health resource settings. Additional components of this study will examine genetic factors for non-communicable diseases. This will be examined both through a cross sectional component, and prospectively (cohort component).",[259,260,261,262,263,264,265,266,267],"Cardiovascular Diseases","Risk Factor, Cardiovascular","Health Behavior","Environmental Exposure","Lung Diseases","Cancer","Injuries","Renal Disease","Communicable Disease",[269],"Non-communicable Diseases, Risk Factors","2024-01-29",{"date":272,"type":37},"2024-01-31",{"date":274,"type":37},"2002-01-01",{"date":276,"type":21},"2030-12-31",{"name":278,"class":44},"Population Health Research Institute",34,""]